Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events.

Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events.
Expert Rev Cardiovasc Ther. 2016 May 23;
Authors: Bliden KP, Tantry US, Chaudhary R, Byun S, Gurbel PA
Abstract
Aspirin has been the bedrock of antiplatelet treatment strategies for the secondary prevention of recurrent cardiovascular and cerebrovascular events for the last 3 decades. The limitations of standard aspirin therapy include bleeding, gastrotoxicity, and loss of antiplatelet effect over a 24-hour period in selected high-risk patients. An extended-release aspirin formulation, Durlaza(®) (New Haven Pharmaceuticals, Inc., North Haven, CT), has been developed to address some of the latter limitations and may provide an alternative to standard aspirin in the secondary prevention of cardiovascular disease.
PMID: 27215735 [PubMed - as supplied by publisher]

Source: Expert Review of Cardiovascular Therapy - May 25, 2016 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research